drugset / Trial / NCT06135545

Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block

NCT06135545 ↗

Withdrawn Shiyou Wei
RandomizedParallel-groupDouble-blindTreatment

Summary

In this study, patients will receive bupivacaine liposome serratus anterior plane block or ropivacaine paraspinal block to manage postoperative pain. Follow-up visits will be conducted to investigate the patient's postoperative pain and recovery quality. The investigators hypothesize that the simple and safe serratus anterior plane block with a novel long-acting local anesthetic (bupivacaine liposome) has analgesic efficacy and recovery quality that is not inferior to the currently commonly used bupivacaine paraspinal block.

Timeline

Start
2023-10-01
Primary completion
2023-10-02
Completion
2023-10-03

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg —
Subject Ropivacaine Other / unclassified 0.5 % Other
Subject Ropivacaine Other / unclassified 20 ml Other

Indications